Haloperidol Krka

Haloperidol Krka is a prescription injectable medication that contains the active ingredient haloperidol. It is supplied as an intravenous solution, marketed in the European Union, and belongs to the butyrophenone antipsychotic class. The product is used under medical supervision for conditions that require dopamine D2 receptor blockade. It is administered by healthcare professionals in hospital or clinic settings and is classified as a prescription‑only (Rx) drug.

Haloperidol Krka is indicated for several psychiatric and neurological conditions where dopamine antagonism is therapeutic, and it may be used in acute or chronic management settings.

- Schizophrenia, including acute exacerbations - Acute psychotic episodes and severe agitation - Manic episodes associated with bipolar disorder - Tourette syndrome with prominent tics - Pre‑operative sedation for patients at risk of severe agitation - Adjunctive treatment for severe agitation in intensive care units

Side effects of Haloperidol Krka vary in frequency and severity; they reflect its dopamine‑blocking activity and can affect multiple organ systems.

Common: - Extrapyramidal symptoms such as tremor, rigidity, and akathisia - Drowsiness or sedation - Dry mouth and constipation - Blurred vision or dizziness

Serious: - Neuroleptic malignant syndrome, a life‑threatening reaction - Torsades de pointes or other significant cardiac arrhythmias - Severe hypotension or respiratory depression

When prescribing Haloperidol Krka, clinicians should evaluate patient history and monitor for specific risks to minimize adverse outcomes.

- Assess for cardiovascular disease, as haloperidol can prolong the QT interval - Use caution in patients with a history of seizures or movement disorders - Monitor elderly patients closely due to increased sensitivity to sedation and falls - Evaluate liver and kidney function, especially in patients with hepatic or renal impairment - Avoid use during pregnancy or lactation unless benefits outweigh risks - Review concomitant medications that affect electrolyte balance or cardiac conduction

Haloperidol Krka can interact with other drugs that influence dopamine pathways, cardiac rhythm, or metabolic clearance, requiring careful medication review.

Avoid: - Other antipsychotics or dopamine antagonists, which may amplify extrapyramidal effects - Medications known to significantly prolong the QT interval (e.g., certain antiarrhythmics, macrolide antibiotics) - Strong CYP3A4 inhibitors such as ketoconazole or clarithromycin, which can raise haloperidol levels

Use with caution: - CNS depressants including benzodiazepines and opioids, due to additive sedation - Antihypertensive agents, because of potential additive hypotensive effects - Drugs that affect electrolyte balance (e.g., diuretics) which may increase